Pfizer/Sangamo Therapeutics report severe adverse event (SAE) from phase 3 AFFINE haemophilia A gene therapy study
Meet Zita Gacser, EHC Think Tank Officer
Announcing: EHC Emergency Displacement Fund (EDF)
With enduring shock and sadness, we think of our community members and others affected by the current challenging times, and are working tirelessly to provide support where possible. The EHC have been working with...
EHC Women’s Committee marks International Women’s Day
EHC VWD Working Group holds a strategic retreat
Meet Daria Mironova, EHC Communications and Public Policy Officer
BioMarin reports a serious adverse event for its phase I/II gene therapy trial for haemophilia A
February 4, 2022 – BioMarin’s gene therapy (valoctocogene roxaparvovec) for haemophilia A is currently in development and not yet licensed by regulators. BioMarin has completed dosing 134 patients in its phase 3 clinical study...
FDA places the Pfizer/Sangamo Therapeutics phase 3 AFFINE haemophilia A gene therapy study on clinical hold
